Cold urticaria – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:03:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cold urticaria – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-barzolvolimab-in-participants-with-cold-urticaria-and-symptomatic-dermographism/ Wed, 29 Apr 2026 15:09:39 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-barzolvolimab-in-participants-with-cold-urticaria-and-symptomatic-dermographism/ This study is being conducted to evaluate the effectiveness of barzolvolimab in people living with Cold Induced Urticaria and Symptomatic Dermographism. Cold Induced Urticaria is a condition where skin reactions, such as hives or itching, occur after exposure to cold temperatures. Symptomatic Dermographism is a condition where skin becomes itchy or raised after being lightly scratched or rubbed. Participants in this study will receive either barzolvolimab or a placebo through subcutaneous injection, which is a method of delivering medication just under the skin. Additionally, epinephrine may be used as a background treatment.

During the study, participants will be assigned to different groups to compare the results of the new medication against the placebo. The process involves monitoring the skin’s reaction to specific triggers over several weeks. The study aims to see if the treatment helps reduce the severity of skin reactions when exposed to cold or physical pressure. Information regarding how the body responds to these triggers will be collected at various stages throughout the study period.

]]> Study on Remibrutinib for Adults with Chronic Inducible Urticaria Uncontrolled by H1-Antihistamines https://clinicaltrials.eu/trial/study-on-remibrutinib-for-adults-with-chronic-inducible-urticaria-uncontrolled-by-h1-antihistamines/ Wed, 29 Apr 2026 15:00:12 +0000 https://clinicaltrials.eu/trial/study-on-remibrutinib-for-adults-with-chronic-inducible-urticaria-uncontrolled-by-h1-antihistamines/ This clinical trial is focused on studying a condition known as Chronic Inducible Urticaria (CINDU), which includes types like symptomatic dermographism, cold urticaria, and cholinergic urticaria. These are conditions where the skin reacts with hives or welts due to specific triggers such as scratching, cold temperatures, or physical activity. The study is testing a new treatment called remibrutinib (LOU064), which is a low molecular weight compound that works by inhibiting a specific enzyme in the body. This treatment is being compared to a placebo to see how effective it is in helping people with CINDU who have not had success with standard treatments like H1-antihistamines, which are medications that block the effects of histamine, a substance in the body that causes allergy symptoms.

The purpose of the study is to determine if remibrutinib can help more people achieve a complete response, meaning their symptoms are fully controlled, compared to those taking a placebo. Participants in the study will take the medication orally, in the form of a film-coated tablet, over a period of 52 weeks. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo, to ensure unbiased results. There is also an open-label extension, which means that after the initial study period, all participants may have the opportunity to receive the actual medication.

Throughout the study, participants will be monitored for any changes in their symptoms and any side effects they may experience. The study aims to provide valuable information on the safety, effectiveness, and tolerability of remibrutinib for people with CINDU. This research could potentially lead to a new treatment option for those who struggle with this challenging condition.

]]> Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-barzolvolimab-for-patients-with-chronic-inducible-urticaria/ Wed, 29 Apr 2026 14:57:52 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-barzolvolimab-for-patients-with-chronic-inducible-urticaria/ This clinical trial is focused on studying a condition known as Chronic Inducible Urticaria, which is a type of skin condition that causes itchy welts or hives. The study is testing a treatment called Barzolvolimab, also known by its code name CDX-0159. This treatment is being compared to a placebo to see how effective it is in helping patients with this condition. The trial aims to find out if different doses of Barzolvolimab can help reduce the symptoms of Chronic Inducible Urticaria, specifically in subtypes like Cold Urticaria and Symptomatic Dermographism.

The study is designed to be a randomized, double-blind, placebo-controlled trial. This means that participants will be randomly assigned to receive either the treatment or a placebo, and neither the participants nor the researchers will know who is receiving which until the study is completed. The trial will last for several weeks, during which participants will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The main goal is to see if the treatment can help patients achieve a negative provocation test, which means they do not develop hives when exposed to certain triggers.

Throughout the study, participants will be monitored to assess the safety and effectiveness of Barzolvolimab. The trial will measure how well the treatment works by looking at changes in the symptoms of Chronic Inducible Urticaria over time. The study will also track any side effects that participants may experience. The results will help determine if Barzolvolimab is a safe and effective treatment option for people with this condition.

]]>